Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City-headquartered clinical-stage biotech and AI-platform company that has spent the past decade industrializing drug discovery via massive in-house wet-lab automation, computer-vision-based cell-phenotype analysis, and proprietary foundation-model training on what the company calls the largest empirically-generated biology dataset in industry. The 2024 reverse-merger with UK competitor Exscientia (acquired for approximately 700 million USD in stock) was the strategic combination that gave Recursion both the generative-chemistry design capability (Exscientia AI) and the perturbational-biology platform (Recursion Maps) under one roof — a positioning that the company markets as the only end-to-end AI-native drug-discovery platform from molecule design to clinical candidate selection.

The platform investment is real and material: more than 75 million USD per year on the BioHive-2 supercomputer (built with NVIDIA on H100/H200 GPUs, with NVIDIA holding a 7.7 percent equity stake from the 2023 strategic investment), more than 2 million experiments per week generated through fully automated wet-lab cells, and active partnerships with Roche-Genentech (53 million USD upfront 2021 plus up to 1.5 billion USD milestones), Bayer (1.5 billion USD initiative for fibrosis and oncology), and Sanofi (3 billion USD milestones for inflammatory and immunology).

The financial reality is harsher than the platform-positioning suggests. Trailing-twelve-month revenue is 66 million USD (down 56 percent year-over-year due to lumpy collaboration milestone timing), operating cash burn is approximately 420 million USD per year (post-Exscientia integration restructuring), cash on the balance sheet is approximately 360 million USD as of Q3 2025, and the company has guided to a Q1-2027 cash-out date absent additional capital raise or material partnership-milestone receipts. The clinical pipeline includes four programs in Phase 1/2 (REC-4881 for familial adenomatous polyposis, REC-617 for solid tumors, REC-1245 for biomarker-enriched solid tumors, REC-3565 for B-cell malignancies) — interesting but early-stage and far from a single approved drug.

The stock has compressed approximately 75 percent from the 2024 post-merger peak of approximately 12 USD to the current 2.93 USD, putting the market capitalization at 1.56 billion USD. The market is pricing the company as a cash-burning clinical-stage biotech with optionality on the AI-platform monetization — not as an AI-platform with embedded therapeutics. The bull-case requires either a material partnership-milestone receipt in 2026, a positive Phase 2 clinical readout, or a strategic acquisition by a large pharma seeking AI-platform-capability. The bear-case is a 2026 dilutive equity raise at sub-3-USD prices that compresses per-share value further while the platform thesis remains unproven.

Recursion has a complex shareholder base reflecting the merged-entity history. NVIDIA holds approximately 7.7 percent post the July 2023 strategic investment (50 million USD at approximately 6.6 USD per share) — NVIDIA has not sold any shares during the 2024-2025 decline. Lux Capital (Bilal Zuberi, deep-tech venture firm) retains 6.2 percent from the pre-IPO 2021 era and has been a vocal supporter at industry conferences. Bayer AG holds approximately 4.1 percent through the strategic partnership equity tranche. BlackRock 4.8 percent, Vanguard 5.9 percent, State Street 2.3 percent (passive trio from Russell 2000 and SP Biotech ETF inclusion).

The notable specialist holders are limited: ARK Investment Management (Cathie Wood) holds 3.4 percent across the ARKK and ARKG funds and has been a net-buyer through the 2024-2025 decline. Baillie Gifford (Edinburgh long-term-growth specialist) initiated a 1.8 percent position in Q2 2025. No US biotech specialist deep-value funds (RA Capital, BVF Partners, Adage) have built meaningful positions — these specialists generally avoid pre-commercial AI-platform biotechs where the cash-burn-to-revenue ratio exceeds 6x. Insider ownership is modest at 3.1 percent (CEO Chris Gibson holds approximately 450.000 shares; CSO Jacob Singer 280.000) and there was meaningful insider buying in Q4 2024 from board chair Robert Hugin (200.000 shares at approximately 4.50 USD) plus CFO Ben Taylor (90.000 shares at 4.20 USD). No insider selling has occurred at sub-5-USD prices since 2024.

At 2.93 USD per share with 532 million shares outstanding (post-Exscientia merger), Recursion has a market capitalization of approximately 1.56 billion USD. The balance sheet shows 360 million USD in cash and short-term investments against approximately 30 million USD in convertible notes — net cash of 330 million USD — for an enterprise value of approximately 1.23 billion USD. The valuation framework cannot be price-to-earnings (negative earnings) or EV-to-sales (revenue is collaboration-lumpy not recurring) — the relevant framework is risk-adjusted net-present-value of the AI-platform plus clinical pipeline, less the present-value of expected dilution from the 2026 equity raise. Wall Street consensus risk-adjusted NPV models cluster at 4-6 USD per share, with the bull-side reaching 8-10 USD on full pipeline success plus strategic-acquisition optionality and the bear-side at 1.50-2.00 USD on cash-burn-exhaustion. Analyst price target consensus is approximately 6 USD (105 percent upside) with the range spanning from 3 USD (bearish) to 12 USD (bullish). The wide dispersion reflects fundamental disagreement on whether the AI-platform thesis is credible at scale. The cash-per-share floor is approximately 0.62 USD per share — but the realistic cash-burn-driven floor pre-equity-raise is approximately 2.00 USD per share. The asymmetric upside is the strategic-acquisition scenario (12-18 USD per share is precedented in this category) or a clean Phase 2 readout (50-100 percent re-rating).

1. 2026 Q1:

   Q4 2025 earnings and 2026 cash-runway guidance — the critical data point is whether management commits to specific cost-cutting milestones or signals an imminent equity raise. Cost-cut commitment without equity raise would be a positive 10-20 percent reaction; an explicit equity-raise announcement would trigger an additional 15-25 percent drawdown.

2. 2026 H2:

   REC-4881 familial adenomatous polyposis Phase 1/2 interim data readout — the highest-conviction clinical signal in the pipeline. Positive polyp-burden reduction signal would validate the AI-platform proof-of-concept and likely trigger a 50-100 percent re-rating plus strategic-acquirer interest renewal.

3. 2026 Q4 to 2027 Q1:

   Strategic acquisition scenario — if Roche, Bayer, Sanofi or NVIDIA conclude that the AI-platform is worth acquiring outright (rather than continuing the partnership pay-as-you-go model), a take-out offer in the 9-15 USD per share range becomes possible. The Lupus and oncology platform-thesis would be the most-attractive standalone-takeout justification.

Recursion Pharmaceuticals is a textbook broken-AI-platform-biotech at distressed valuation with strategic-acquirer optionality setup that requires a 24-36-month investment horizon and a stomach for binary outcomes. The strategic positioning is real and unique (end-to-end AI-native drug-discovery platform post-Exscientia merger, NVIDIA partnership, three top-pharma collaborations), but the financial reality is harsh (420 million USD per year cash burn against 360 million USD cash, dilutive equity raise almost-certain in 2026, no AI-discovered drug has yet received FDA approval). The bull-case path requires either a clean Phase 2 readout (REC-4881 FAP in H2 2026 is the most-likely) or a strategic acquisition by Roche-Bayer-Sanofi-NVIDIA at 9-15 USD per share — both possible but neither guaranteed. The bear-case path is dilutive equity raise at sub-3-USD followed by another 6-12 months of cash-burn before the next clinical-data inflection, putting the stock at 1.50-2.00 USD floor. Position sizing should reflect that this is a venture-stage public-equity bet — appropriate for a 0.5-1.5 percent portfolio position with binary outcome distribution. NVIDIA, Lux Capital and Baillie Gifford holding meaningful positions is a real signal of platform-credibility, but the absence of biotech-specialist deep-value money (RA Capital, BVF, Adage) is the bearish counter-signal. Trade or pass — not a hold-and-forget compounder until the FAP readout proves the AI-platform thesis or a strategic acquirer steps in with a take-out premium.